Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 8, 2024

Clinical Evidence for Emerging PAH Therapies

Dr Oudiz discusses clinical data that support the efficacy and safety of emerging PAH therapies and ongoing research in the treatment space.

Episodes in this series

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 1 Evolving Guidelines for PAH Treatment

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 2 New Therapeutic Frontiers in PAH

Ioana Preston, MD, a pulmonologist

EP. 3 Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

Ioana Preston, MD, a pulmonologist

EP. 4 Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

Marius Hoeper, MD, an expert on PAH

EP. 5 Breaking Down the PAH Cost Burden

Marius Hoeper, MD, an expert on PAH

EP. 6 A New Era in PAH Treatment?

"Clinical Evidence for Emerging PAH Therapies"

EP. 7 Clinical Evidence for Emerging PAH Therapies

"Integrating New PAH Therapies into Clinical Practice"

EP. 8 Integrating New PAH Therapies into Clinical Practice

Ioana Preston, MD, a pulmonologist

EP. 9 Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

Marius Hoeper, MD, an expert on PAH

EP. 10 FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 11 Overcoming Barriers to Better Patient Outcomes in PAH

Ioana Preston, MD, a pulmonologist

EP. 12 Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

Marius Hoeper, MD, an expert on PAH

EP. 13 Optimizing PAH Care Delivery for Better Outcomes

Marius Hoeper, MD, an expert on PAH

EP. 14 Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following questions:

What clinical data support the efficacy and safety of these new treatments, and how do they compare to existing therapies?
Are there any ongoing clinical trials evaluating promising investigational agents or combination therapies for pulmonary arterial hypertension (PAH)?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

AJMC original research clinical

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Experts featured in this series.

Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

July 23rd 2026

Experts featured in this series.

The Role of Radiotherapy in Advanced Follicular Lymphoma

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

July 23rd 2026

Man having heart attack - dragonstock - stock.adobe.com

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

ByPearl Steinzor

July 22nd 2026

David Zhang

Challenges to Clinical Implementation of IPF Polygenic Risk Scores: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 22nd 2026

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape

The Role of Radiotherapy in Advanced Follicular Lymphoma